Stoke Therapeutics, Inc. (STOK)
After hours:
| Previous close | 11.69 |
| Open | 11.60 |
| Bid | 12.36 x 100 |
| Ask | 12.44 x 600 |
| Day's range | 11.49 - 12.43 |
| 52-week range | 3.35 - 16.40 |
| Volume | |
| Avg. volume | 1,210,439 |
| Market cap | 646.778M |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
- Benzinga
Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients
Monday, Stoke Therapeutics Inc (NASDAQ:STOK) released new data from two open-label Phase 1/2a studies and two open-label extension (OLE) studies of children and adolescents ages 2 to 18 with Dravet syndrome who were treated with STK-001. Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged, and refractory seizures. Data showed clinically meaningful effects, including substantial and durable reductions in convulsive seizure frequency and improvements i
